

Resource Summary Report

Generated by ASWG on Aug 10, 2026

Brilliant Violet 785(TM) anti-human CD2

RRID:AB_2800717

Type: Antibody

Proper Citation

BioLegend Cat# 300234, RRID:AB_2800717

Antibody Information

URL: http://antibodyregistry.org/AB_2800717

Proper Citation: BioLegend Cat# 300234, RRID:AB_2800717

Target Antigen: CD2

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-human CD2

Description: This monoclonal targets CD2

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone RPA-2.10

Antibody ID: AB_2800717

Vendor: BioLegend

Catalog Number: 300234

Alternative Catalog Numbers: 300233

Record Creation Time: 20250819T205258+0000

Record Last Update: 20250819T210747+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-human CD2.

No alerts have been found for Brilliant Violet 785(TM) anti-human CD2.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Bennstein SB, et al. (2026) A single-cell transcriptional reference for the functional and developmental diversity of neonatal innate lymphoid cells. Cell reports, 45(3), 117000.

Biederstädt A, et al. (2025) Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency. Cancer cell.

Füchsl F, et al. (2024) High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells. Nature communications, 15(1), 10520.

Li S, et al. (2023) Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells. Cell reports, 42(3), 112241.